SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-QSB/A
(MARK ONE)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
----- EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED
JUNE 30, 2000 OR
_____ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______ TO______
COMMISSION FILE NUMBER: 0-30619
TRINITY MEDICAL GROUP USA, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<CAPTION>
<S> <C>
FLORIDA 68-0438943
--------------------------------------------------- ----------------------------------------
(STATE OR OTHER JURISDICTION OF INCORPORATION) (I.R.S. EMPLOYER IDENTIFICATION NO.)
</TABLE>
3753 HOWARD HUGHES PARKWAY, 2ND FLOOR, LAS VEGAS, NV 89109
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES WITH ZIP CODE)
(415) 256-1995
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
N/A
(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST
REPORT)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES X NO
______ ______
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING
THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Section 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court. YES___ NO_____
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest date.
Class Outstanding at August 31, 2000
Common Stock - $0.001 par value 10,226,000 shares
<PAGE>
INDEX
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
COVER PAGE.............................................................................................1
INDEX..................................................................................................2
PART I - FINANCIAL INFORMATION
Item 1 - Interim Financial Statements
Balance Sheets......................................................................3
Statements of Operations............................................................4
Statements of Cash Flows............................................................5
Condensed Notes to Financial Statements.............................................6
Item 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations.......................................8
PART II - OTHER INFORMATION
Item 2 - Changes in Securities and Use of Proceeds...........................................10
Item 6 - Exhibits and Reports on Form 8-K....................................................11
</TABLE>
2
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1. INTERIM FINANCIAL STATEMENTS
TRINITY MEDICAL GROUP USA, INC.
(a company in the development stage)
BALANCE SHEETS
<TABLE>
<CAPTION>
ASSETS
June 30, December 31,
2000 1999
------------ ------------
(unaudited)
Current Assets:
<S> <C> <C>
Cash $ 33,303 $ 171,485
Subscription receivable from founding shareholders - 9,600
Income tax refund receivable 18,951 18,951
---------------------- ----------------------
Total current assets 52,254 200,036
Computer Equipment 2,100 -
---------------------- ----------------------
Total assets $ 54,354 $ 200,036
====================== ======================
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable $ 2,000 $ 10,343
Payable to TMG 200,000 -
Accrued commissions 76,700 73,250
Accrued interest payable 48,648 11,345
---------------------- ----------------------
Total current liabilities 327,348 94,938
Convertible Notes Payable 772,500 732,500
Stockholders' deficit:
Common stock, $0.001 par value, 50,000,000 shares authorized,
10,226,000 shares issued and outstanding 10,226 10,226
Deposits on common stock units 31,050 -
Additional paid-in capital 228,574 228,574
Deficit accumulated during the development stage (1,315,344) (866,202)
---------------------- ----------------------
Total stockholders' deficit (1,045,494) (627,402)
---------------------- ----------------------
Total liabilities and stockholders' deficit $ 54,354 $ 200,036
====================== ======================
</TABLE>
The accompanying notes are an integral part of these statements.
3
<PAGE>
TRINITY MEDICAL GROUP USA, INC.
(a company in the development stage)
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
Cumulative Three Months Six Months
from inception Ended Ended
to June 30, June 30,
June 30, 2000 2000 2000
----------- ----------- -----------
(unaudited) (unaudited) (unaudited)
Operating expenses
<S> <C> <C> <C>
Research and development $ (494,000) $ (200,000) $ (200,000)
General and administrative
Acquisition costs (404,200) - -
Administrative costs (284,950) (85,035) (212,959)
Marketing costs (78,250) - -
---------------- ----------------- -------------------
Total operating expenses (1,261,400) (285,035) (412,959)
Other income (expense):
Interest income 3,148 78 1,120
Interest expense (48,647) (18,645) (37,303)
Loss on sale of investments (8,445) - -
---------------- ----------------- -------------------
(53,944) (18,567) (36,183)
---------------- ----------------- -------------------
Net Loss $ (1,315,344) $ (303,602) $ (449,142)
================ ================= ===================
Basic and diluted loss per common
share $ (0.03) $ (0.04)
================= ===================
Basic and diluted weighted average common shares
outstanding 10,226,000 10,226,000
================= ===================
</TABLE>
The accompanying notes are an integral part of these statements.
4
<PAGE>
TRINITY MEDICAL GROUP USA, INC.
(a company in the development stage)
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
Cumulative
from inception
to Six Months Ended
June 30, 2000 June 30, 2000
------------- -------------
(unaudited) (unaudited)
Cash flows from operating activities:
<S> <C> <C>
Net loss $ (1,315,344) $ (449,142)
Adjustments to reconcile net loss to net cash used in
operating activities
Stock issued for services 229,200 -
Loss on sale of investments 8,445 -
Changes in assets and liabilities:
Income tax refund receivable (18,952) -
Accounts payable 2,000 (8,343)
Payable to TMG 200,000 200,000
Accrued liabilities 125,349 40,753
------------------ ------------------
Net cash used in operating activities (769,302) (216,732)
------------------ ------------------
Cash flows from investing activities:
Purchase of fixed assets (2,100) (2,100)
Purchase of investments (69,330) -
Proceeds from sale of investments 60,885 -
------------------ ------------------
Net cash used in investing activities (10,545) (2,100)
------------------ ------------------
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable 772,500 40,000
Net proceeds from sale of common stock not issued at period end 31,050 31,050
Collection of subscription receivable 9,600 9,600
------------------ ------------------
Net cash provided by financing activities 813,150 80,650
------------------ ------------------
Net increase (decrease) in cash 33,303 (138,182)
Cash - beginning of period - 171,485
------------------ ------------------
Cash - end of period $ 33,303 $ 33,303
================== ==================
Non-cash investing and financing activities:
Issuance of common stock to founding shareholders in exchange
for subscription receivable $ 9,600 $ -
================== ==================
</TABLE>
The accompanying notes are an integral part of these statements.
5
<PAGE>
TRINITY MEDICAL GROUP USA, INC.
(a company in the development stage)
CONDENSED NOTES TO FINANCIAL STATEMENTS
NOTE A - BASIS OF PRESENTATION
The accompanying unaudited financial statements contain all adjustments
(consisting only of normal recurring adjustments) which in the opinion of
management are necessary to present fairly the financial position of the Company
at June 30, 2000, and the results of its operations and its cash flows for the
three and six month periods ended June 30, 2000. The financial statements do not
include comparative second quarter information because the Company had no
activity during the six month period ended June 30, 1999. Certain information
and footnote disclosures normally included in financial statements have been
condensed or omitted pursuant to rules and regulations of the Securities and
Exchange Commission, although the Company believes that the disclosures in the
financial statements are adequate to make the information presented not
misleading.
The financial statements included herein should be read in conjunction with the
financial statements included in the Company's Form 10-SB as of December 31,
1999 and for the period from inception (September 28, 1998) to December 31,
1999, filed with the Securities and Exchange Commission on May 12, 2000.
NOTE B - PROPERTY AND EQUIPMENT
Property and equipment are recorded at cost. Depreciation is provided using the
straight-line method over the useful lives of the related assets, which ranges
from three to five years. The cost and related accumulated depreciation of
equipment sold or otherwise disposed of are removed from the accounts and the
resulting gain or losses are included in the statement of operations.
NOTE C - GOING CONCERN
The accompanying financial statements have been prepared on a going concern
basis, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business. As shown in the financial
statements, the Company is in the development stage and, at June 30, 2000 has
accumulated losses amounting to $1,315,344. For the six month period ended June
30, 2000, and for the period from inception to June 30, 2000 the Company used
$216,732 and $769,302, respectively, of cash in its operations. The drug
therapy, Remune, must undergo several phases of trial testing before approval by
the Thailand government can be obtained and significant commercialization of the
drug can occur. This additional testing will require significant additional
financing. These factors, among others, raise substantial doubt about the
Company's ability to continue as a going concern. The financial statements do
not include any adjustments relating to the recoverability and classification of
recorded asset amounts or the amounts and classification of liabilities that
might be necessary should the Company be unable to continue as a going concern
for a reasonable period of time.
6
<PAGE>
TRINITY MEDICAL GROUP USA, INC.
(a company in the development stage)
CONDENSED NOTES TO FINANCIAL STATEMENTS
The Company intends to acquire, in the near term, the rights to Remune and
assume the related obligations specified under the Stock Purchase Agreement from
TMG. The Company intends to market Remune in the countries where it has the
rights through partner or affiliated firms, which will carry out the local
regulatory requirements, distribution, and product support. The Company intends
to finance the aforementioned activities through a secondary offering. The
Company's initial efforts have focused on the research and development of Remune
(through TMG) and securing sales and marketing rights in Thailand.
There can be no assurance that management will be successful in raising the
necessary funds to complete the clinical trials and obtain the necessary
government approvals for the manufacturing and sale of Remune. The Company's
ability to continue as a going concern will depend upon these factors and the
success of future operations.
NOTE D- CONVERTIBLE NOTES PAYABLE
During the six months ended June 30, 2000, the Company sold 8 units of its
convertible notes payable at a price of $5,000 per unit to accredited investors
in a private placement offering. Each unit consists of a $5,000, 10% note due
August 30, 2001. Each unit is convertible into 5,000 shares of the Company's
common stock at the election of the Company. Interest accrued on each unit is
convertible to common stock at a rate of $1 per share at the date of conversion.
As of June 30, 2000, no units had been converted to common stock.
NOTE E- COMMON STOCK UNITS
On June 21, 2000, the Company began to raise additional capital under a private
placement offering. A maximum of 175 preferred stock units at $4,000 per unit
were initially offered in the private placement. Because the Company was not
authorized to issue preferred stock, the units were subsequently changed to
common stock units. Each unit consists of one thousand shares of the Company's
Common Stock, par value $.001, and a non-callable common stock purchase warrant
(the "Warrant"). Each of the Warrants entitles the registered holder to purchase
up to one thousand shares of the Common Stock at a price of $4.00 per share for
a period of 24 months from the date of the Private Placement Prospectus, July
24, 2000. The Common Shares and the Warrant included in the units will not be
separately transferable until 90 days after the date of the Prospectus or such
earlier date as the Company may determine. The Company received net proceeds of
$31,050 under this private placement offering during the three months ended June
30, 2000, after commissions paid or accrued. Subsequent to June 30, 2000, the
Company received an additional $600,000 through this private placement offering.
Because the Company has not issued the common stock subscribed as of June 30,
2000, it has presented the net proceeds of $31,050 as Deposits on Common
Stock Units in the accompanying balance sheet.
NOTE F - RELATED PARTY TRANSACTIONS
During the three months ended June 30, 2000, the Company recognized $200,000 of
expense related to the research and development of the drug Remune. The $200,000
is owed to Trinity Medical Group, Ltd., an affiliate of the Company, and has
been presented on the accompanying balance sheet as Payable to TMG at June 30,
2000. These research and development expenses were incurred under the terms and
conditions of the Collaboration and Supply Agreement, dated December 1, 1999.
7
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Forward-Looking Statements
--------------------------
This report contains certain forward-looking statements which involve
substantial risks and uncertainties. These forward-looking statements can
generally be identified because the context of the statement includes words such
as "may," "will," "expect," "anticipate," "intend," "estimate," "continue,"
"believe," or other similar words. Similarly, statements that describe our
future plans, objectives and goals are also forward-looking statements. Our
factual results, performance or achievements could differ materially from those
expressed or implied in these forward-looking statements as a result of certain
factors, including those listed in this report.
Plan of Operation
-----------------
Trinity Medical Group USA, Inc. (the "Company") was incorporated in the State of
Delaware on September 28, 1998 and reincorporated in Nevada in November of 1999
with its principal place of business in California. In December 1999, as the
result of a reorganization, the Company became a Florida corporation. The
Company is an affiliate of Trinity Medical Group, Ltd., a Thailand company
(http: //www.trinitygroups/trinity medical/dsmb.htm) ("TMG"). The Company is a
late development stage company with potential rights to market a patented
vaccine, ("Remune"), designed to induce specific T cell responses in people
infected with the Human Immunodeficiency Virus (HIV). Remune (an immune-based
therapy consisting of whole inactivated HIV-1 virus depleted of its gp120 coat
protein) is based on Dr. Jonas Salk's vaccine technology.
TMG was formed in 1995 after the principals of the TMG and The Immune Response
Corporation (NASDAQ: IMNR) entered into a License and Collaboration Agreement
(the "License and Collaboration Agreement") dated September 15, 1995 with The
Immune Response Corporation to develop and market Remune in ten Southeast Asian
countries including Malaysia, The Philippines, Singapore, Sri Lanka, Myanmar,
Laos, Cambodia, Vietnam and Indonesia, with Thailand as the lead nation (the
"Territory"). On the same day, TMG entered into a Stock Purchase Agreement (the
"Stock Purchase Agreement") with The Immune Response Corporation. Per the Stock
Purchase Agreement, TMG purchased 333,334 shares of The Immune Response
Corporation's stock at $15 per share on April 30, 1996. TMG is further obligated
to purchase an additional 333,333 shares of The Immune Response Corporation's
stock at $15 per share upon receiving the required marketing approval from the
governing health authority of Thailand for the drug therapy Remune. TMG is
further obligated to purchase another 333,333 shares of The Immune Response
Corporation's stock at $15 per share upon receiving the required factory
establishment license or approval from the governing health authority of
Thailand to manufacture the drug therapy Remune.
The Company entered into a Collaboration and Supply Agreement (the "Agreement")
with TMG, dated December 1, 1999. Under the terms of the Agreement, the Company
will pay TMG for specified research personnel, travel, laboratory, facility and
publication costs associated with clinical trials of Remune until full
regulatory approval in Thailand is granted.
The Agreement also provides that the Company make its best efforts to capitalize
itself with at least $4,000,000 through sale or subscription of common class
shares not to exceed 1 million shares. The Company also agreed to prepare and
complete all necessary documentation required for registration of the Company
with the U.S. Securities and Exchange Commission as a reporting company, which
it has done by filing a Form 10-SB on May 12, 2000.
In exchange for the aforementioned conditions, TMG agrees to transfer its
License and Collaboration Agreement and Stock Purchase Agreement between it and
The Immune Response Corporation, dated
8
<PAGE>
September 15, 1995, to the Company no later than the first sale of product after
full regulatory approval in Thailand has been granted.
In 1999, TMG completed a Phase II double blind placebo controlled clinical trial
in Thailand, the results of which were submitted to the Thailand National
Committee on AIDS for review in March, 2000. In the clinical trial above, Remune
was found to increase mean CD4+ cell counts, with increases in both cellular and
humoral immune responses and stable viral load. A follow up study through
eighty-eight (88) weeks showed a significant decrease of viral load in 30% of
the subjects.
On December 24, 1999, TMG applied for expanded testing with the Ministry of
Public Health in Thailand. The extended project will be coordinated by Mahidol
University in Bangkok, Thailand and will confirm the effectiveness of Remune and
study the long term effects of Remune on up to 10,000 HIV infected individuals.
This extended study of Remune is not connected to the request for full
commercial approval by the Thai Food and Drug Administration.
The results of the Phase II controlled trial were presented at the XIII
International AIDS Conference in Durban, South Africa by Dr. Vina
Churdboonchart. The results of the Phase II clinical trials in Thailand and
other clinical trials using Remune as a treatment for slowing HIV-related
disease progression are encouraging. The global burden of disease and death
related to HIV is increasing at a rate unmatched by any other pathogen. At
present, the most effective treatment for slowing HIV-related disease
progression, antiretoviral medication requiring a daily multi-pill regime, is
complicated to administer, requires close medical monitoring, is extremely
costly, and can cause significant adverse effects in some cases. The study
conditions of the clinical trials in Thailand allowed Remune to be assessed as a
"mono-therapy", that is, without any other anti-viral drugs. Remune requires a
minimum of a once a quarter (or more if needed) injection. As a result, Remune
is both more economical and practical for populations such as Thailand. As
released by MOPH, Thailand, the official number of HIV infected people in
Thailand is 1 million people. The estimate for Southeast Asia is approximately 9
million HIV-1 infected people. Remune is potentially a very cost effective
therapy for the treatment of HIV among Thailand's poorest people.
Cash requirements over the next 12 months.
------------------------------------------
Pursuant to a private offering (the "December Private Placement"), the Company
raised $732,500 at the end of 1999 and an additional $40,000 during the six
month period ended June 30, 2000. In the December Private Placement, the Company
offered for purchase to accredited investors 154.5 units at a price of $5,000
per unit. Each unit consisted of a $5,000, 10% per annum note of the Company due
August 31, 2001 convertible into 5,000 shares of the Company's Common Stock, par
value $.001 per share (collectively, the "Units").
Over the next 12 months, the Company will require additional capital through the
sale of shares of capital stock or issuance of debt in order to meet its
business needs. The Company anticipates revenue from sale of Remune in Thailand
later this year. The Company is in the process of negotiating Remune licensing
agreements and, if completed, anticipates substantial revenue from licensing
Remune in other countries during the year but cannot predict the amount of
proceeds or the timing of the completion of such transactions.
The current cash on hand will be sufficient to fund operations through the
third quarter of 2000. During the second quarter the Company received net
proceeds of approximately $31,000 in connection with a private offering (the
"June Private Placement") through the subscription of common stock units and
received proceeds of $600,000 during the third quarter of 2000 from this Private
Placement. In the third quarter the Company plans to file a registration
statement to register the shares of common stock issuable under the December
Private Placement and the June Private Placement. The Company hopes to raise
additional capital in the third quarter. The Company plans to use the proceeds
raised to satisfy the Stock Purchase Agreement with The Immune Response
Corporation,
9
<PAGE>
export Remune to Thailand, and to cover initial expenses for the establishment
of Thai manufacturing facilities as well as The Trinity Immune and Health Center
which will primarily cater to the HIV+ population.
Product Research and Development Plans
--------------------------------------
The Company intends to secure regulatory approval for sale of Remune in Thailand
during the calendar year 2000. TMG's researchers have concluded a Phase II
clinical study in Thailand of about 300 individuals infected with HIV and
continue to analyze the study group. The results of this study were presented at
five major scientific conferences in 2000: at the UN/WHO AIDS conference in
Geneva, Switzerland, the UCLA AIDS Conference held in Palm Springs, California,
the 5 Asia-Pacific Congress of Medical Virology in Bali, Indonesia, the First
International Conference of Vaccine Development and Immunotherapy in HIV,
Florida, USA and the XIII International AIDS Conference in Durban, South Africa.
The Company believes it now has the necessary technical support for full
regulatory approval and through its Thai affiliates will be submitting an
application for commercialization of Remune to the Thai regulatory officials.
Upon sufficient capitalization, the Company intends to purchase plant, equipment
and land leases in 2000 for a handling and storage facility in Thailand. The
facility will be located close to the Bangkok International Airport and will
receive Remune shipment in bulk. The facility will be built to U.S. FDA Good
Manufacturing Practice standards and provide for climate controlled and secure
warehousing. The estimated cost for the facility is $5 million and will require
six months to one year to construct. The capital for this project would be
provided by product revenue and the sale of shares of capital stock, issuance of
debt or financing by a banking institution. The Company intends to increase its
employment base in the third quarter of 2000. The Company intends to add a Chief
Financial Officer, engineering consultants and additional directors during the
third quarter. From its present level of two employees the Company estimates
having about 10 employees by year-end.
PART II - OTHER INFORMATION
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
Pursuant to an Agreement for the Exchange of Common Stock, dated December 31,
1999, between the shareholders of the Company and August Project III Corp., a
Florida corporation ("August Project"), August Project issued to the Company's
shareholders 5,226,000 shares of Common Stock in exchange for 100% of the
outstanding shares of the Company. In addition, certain shareholders of August
Project sold 4,867,000 shares to the shareholders of the Company in exchange for
$175,000. Following the merger, the shareholders of the predecessor Company
owned a total of 10,093,000 out of a total of 10,226,000 outstanding shares of
August Project. August Project was the surviving corporation after the merger.
Prior to the merger, August Project had been approved for listing on the
National Quotation Service Pink Sheets with the following trading symbol: AUUK.
On January 5, 2000, August Project changed its name to Trinity Medical Group
USA, Inc.
In connection with the December Private Placement the Company issued 154.5
notes. The notes were sold to "accredited investors", as that term is defined in
Regulation D promulgated under the Securities Act of 1933, as amended, (the
"Securities Act"). The notes were sold in Units. Each Unit cost $5,000 and
consisted of a $5,000, 10% per annum note of the Company due August 31, 2001
convertible into 5,000 shares of the Company's common stock, $0.001 par value,
per share (the "Notes"). The aggregate offering price was $772,500 and the
Company received net proceeds in the amount of $772,500. The Company believes
that the exemption afforded by Section 4(2) of the Securities Act and Regulation
D promulgated thereunder, is applicable to the above issuances as a transaction
by an issuer not involving a public offering. The proceeds from this private
placement were used to satisfy the Company's initial developmental business
expenses.
On May 12, 2000 the Company submitted a Form 10-SB to the SEC in order to become
a publicly reporting company. On May 19, 2000 the SEC notified the Company that
the filing was acknowledged and would not need to be reviewed; thus allowing the
Company to proceed with its plans. The Company shares now trade
10
<PAGE>
under the symbol TMGU in the National Quotation Service Pink Sheets. The Company
is presently seeking listing on NASD Over the Counter Bulletin Board exchange
and hopes to have listing on the Small Cap NASDAQ market in the fourth quarter.
The Company has paid no dividends on its common stock and cannot assure that it
will achieve sufficient earnings to pay cash dividends on its common stock in
the near future. Further, the Company intends to retain earnings to fund its
operations. Therefore, the Company does not anticipate paying any cash dividends
on its common stock in the foreseeable future.
In connection with a June Private Placement the Company initially issued 9
Preferred Stock Units at $4,000 per unit. Because the Company was not authorized
to issue preferred stock, the units were subsequently changed to Common Stock
Units. The units were sold to "accredited investors", as that term is defined in
Regulation D promulgated under the Securities Act of 1933, as amended, (the
"Securities Act"). Each unit consists of one thousand shares of the Company's
Common Stock, par value $.001, and a non-callable common stock purchase warrant
(the "Warrant"). Each of the Warrants entitles the registered holder to purchase
up to one thousand shares of the Common Stock at a price of $4.00 per share for
a period of 24 months from the date of the Private Placement Prospectus, July
24, 2000. The Common Shares and the Warrant included in the units will not be
separately transferable until 90 days after the date of the Prospectus or such
earlier date as the Company may determine. The Company received net proceeds of
approximately $31,000 under this private placement offering during the three
months ended June 30, 2000. Subsequent to June 30, 2000, the Company received an
additional $600,000 through this private placement offering. The proceeds from
this private placement will be used to meet the Company's continuing operating
expense requirements, including the cost of filing the aforementioned
Registration Statement.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
A) EXHIBITS:
4.1 Common Stock Unit Acknowledgement Letter
27 Financial Data Schedule
B) REPORTS ON FORM 8-K
The Company did not file any reports on Form 8-K during the six months
ended June 30, 2000.
11
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
TRINITY MEDICAL GROUP USA, INC.
Date: November 14, 2000 By: /s/ James Namnath
-----------------
James Namnath
Chief Executive Officer
Date: November 14, 2000 By: /s/ Gary E. Wilson
-----------------
Gary E. Wilson
Executive Vice President-
Finance,
Chief Financial Officer
12
